India's Zydus Cadila Healthcare has around 10 vaccines under development and plans to launch them in India next year, the company said in an earnings call that followed full-year results, entering a busy market in the country that sees a mix of major foreign and domestic players.
The call, reported by DNA India, came after the company reported on May 15 that net profit rose 43% to 11.51 billion rupees ($185.65 million) for the year ended March 31. The DNA India story did not specify the types of vaccines.
India is one of the world's top vaccinemakers and several companies there, including the Serum Institute of India, are regularly prequalified to sell to global vaccination efforts by the World Health Organization.
The country is also a key market for Pfizer ($PFE), Sanofi ($SNY) and GlaxoSmithKline ($GSK), which has placed a large stake in vaccines with the Novartis ($NVS) transaction.
- here's the Zydus Cadila earnings release (PDF)
- and the story from DNA India